DC3 Therapeutics

What DC3 Therapeutics does

DC3 Therapeutics is a privately held, full-service contract research organization (CRO) headquartered in South San Francisco, California, founded in 2013 by a team of industry scientists with prior experience as CRO consumers. The company provides preclinical drug discovery and development services to biotechnology and pharmaceutical clients, spanning target identification and validation, candidate development, preclinical and IND-enabling studies, clinical biomarker support, and companion diagnostics development. Its technical platform integrates cell and molecular biology (including CRISPR/Cas9 and TALEN genome editing, qRT-PCR, dPCR, and next-generation sequencing), biochemical and cell-based screening assays with access to a 100K compound library, protein chemistry, immunohistochemistry and spatial biology with quantitative digital pathology, and CLIA-certified, COLA-accredited clinical chemistry. The company emphasizes a partner-oriented, consultative engagement model positioned against what it describes as the transactional, lower-data-quality experience of traditional CROs, with named enterprise clients including Genentech, Gilead, Bristol Myers Squibb, Revolution Medicines, and CymaBay Therapeutics.

DC3 operates on a fee-for-service professional services model, with revenue generated through custom project engagements requiring consultation and proposal requests. Go-to-market is direct enterprise field sales to biotech and pharma R&D leadership, supplemented by a Science Exchange Verified Supplier marketplace listing and a LinkedIn presence. The firm is fully owned and operated by its leadership and advisors with no disclosed venture capital, private equity, or institutional investment, and operates from a single South San Francisco laboratory with 11-50 employees. Certifications (CLIA, COLA) and a marquee client roster constitute the primary trust signals, while no patents, AI/ML capabilities, or external funding have been disclosed.

Name

DC3 Therapeutics

Legal name

DC3 Therapeutics

Website

https://dc3therapeutics.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

DC3 Therapeutics is a privately held, full-service preclinical CRO in South San Francisco providing drug discovery, IND-enabling, biomarker, and companion diagnostics services to biotech and pharma clients from a CLIA-certified, COLA-accredited lab.

Ownership category

akta.pro rank

Product category

Contract Research Services (Preclinical Drug Discovery and Development)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Contract research services
• Preclinical drug development
• Drug discovery CRO
• Biomarker assay services
• Companion diagnostics development

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Fee-for-service CRO model providing preclinical drug development services on a project basis. Services span discovery, candidate development, preclinical/IND-enabling studies, and clinical biomarker support. Revenue is generated through custom project engagements with biotech and pharma clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

DC3 Therapeutics is a Contract Research Organization (CRO) that provides preclinical drug discovery and development services for biotech and pharmaceutical clients. Offerings span discovery (target identification, validation, mechanism-of-action), preclinical/IND-enabling studies (toxicology, pharmacokinetics, in vitro ADMET, in vivo work), clinical biomarker assays, and companion diagnostic development. Services are delivered through a CLIA-certified, COLA-accredited laboratory in South San Francisco, including cell and molecular biology, biochemical/biophysical/cell-based assays, protein chemistry, IHC and spatial biology, and program management consulting.

Product overview

DC3 Therapeutics is a Contract Research Organization (CRO) offering an integrated suite of drug discovery and pre-clinical development services, operating as a unified platform of scientific expertise rather than discrete software products. The portfolio spans Discovery Solutions (target validation, genome editing, gene expression, functional biology), Pre-clinical/IND-enabling Studies (toxicology, pharmacokinetics, ADMET, in vivo studies), Clinical Studies (biomarker assays, LDTs), and Companion Diagnostics Development—all supported by core laboratory services including Cell & Molecular Biology, Biochemical/Cell-Based Assays, Protein Chemistry, IHC & Spatial Biology, Clinical Chemistry, and Program Management & Consulting. Services are delivered through a CLIA-certified, COLA-accredited laboratory environment in South San Francisco, positioning DC3 as a full-service CRO partner for biotech and pharma clients from discovery through clinical readiness.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell and Molecular Biology Services Advanced cell engineering, genomic manipulation, and molecular profiling for biotech and pharma clients, including CRISPR/Cas9 and TALEN genome editing, gene expression analysis (qRT-PCR, dPCR), and Sanger and next-generation sequencing.
• Biochemical, Biophysical, and Cell-Based Assay Services Custom and high-throughput functional validation and screening assays including apoptosis, viability, cytotoxicity, reporter gene, enzymology, kinase, signal transduction, metabolism, and protein-protein interaction assays, with compound screening in 96- and 384-well formats and access to a 100K compound library.
• Protein Chemistry and Biochemistry Services Recombinant protein production and functional analysis using bacterial, mammalian, and baculovirus expression systems, including protein purification and functional assays, for biotech and pharma research programs.
• IHC and Spatial Biology Services Comprehensive histology and imaging services to map tissue-level expression, including trimming, processing, embedding, serial sectioning, IHC, IF, ISH, FISH, and digital pathology with quantitative image analysis.
• Clinical Chemistry Services COLA-accredited and CLIA-certified testing and biomarker analysis across multiple matrices including urine, serum, blood, and plasma, covering clinical chemistry markers such as BUN, creatinine, glucose, HbA1c, and liver enzymes.
• Program Management and Consulting Services Strategic guidance and cross-functional integration supporting study design through interpretation, serving as a scientific extension of internal teams for assay optimization, biomarker validation, and diagnostic deployment.
• Discovery Solutions Early-stage drug discovery support including target identification, target validation, and mechanism-of-action studies using genome editing, gene expression, and functional biology tools, for biotech and pharma clients.
• Preclinical / IND-Enabling Studies Solutions Regulatory-grade preclinical development support including toxicology, pharmacokinetics, in vitro ADMET, and in vivo studies designed for IND submission readiness, delivered with GLP-like documentation support.
• Clinical Studies Solutions Clinical biomarker discovery and lab-developed testing services operating under CLIA certification with GCP-aligned workflows for safety biomarkers, pharmacodynamic responses, and patient stratification.
• Companion Diagnostics Development Companion diagnostic development from tissue-based spatial biology to multiplexed molecular platforms, including assay design, performance validation, and regulatory pathway alignment, supported by DC3's CLIA-certified lab environment.
• Lab-Developed Tests (LDTs) Custom lab-developed tests developed and performed under CLIA certification for biomarker assays and companion diagnostic support in DC3's CLIA-certified laboratory environment.
• Regulatory Consulting Services Consulting services to align data with IND submission requirements, including GLP-like documentation, custom LDT development, and digital pathology support for regulatory-ready proof of concept.

Quantifiable outcome

• Projects completed on time and on budget with collaborative assay design

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key highlights1 record

Customer concentration

• LinkedInlinkedin.com/company/1759611
• Facebookfacebook.com/DC3-Therapeutics-1651029161820840

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DC3 Therapeutics